SCHEMBL24124176

SCHEMBL24124176

CN(Cc1ccc(NC(=O)c2ccc3c(c2)N(C)C(=O)CS3)cc1)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 13/20 0.54
▸ MEN1 O00255 6/20 0.54
▸ KMT2A Q03164 6/20 0.54
▸ HTT P42858 4/20 0.54
▸ SMN1; SMN2 Q16637 3/20 0.54
▸ OPRM1 P35372 1/20 0.54
▸ OPRD1 P41143 1/20 0.54
▸ LMNA P02545 2/20 0.53
▸ POLB P06746 2/20 0.50
▸ ALDH1A1 P00352 4/20 0.49
▸ MAPK1 P28482 5/20 0.48
▸ USP2 O75604 4/20 0.48
▸ TP53 P04637 3/20 0.48
▸ GAA P10253 1/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ NPC1 O15118 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ TAAR1 Q96RJ0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24124264 0.84 MAPT (0.57) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL24125182 0.80 ALDH1A1 (0.55) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL24124884 0.79 MAPT (0.64) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL24124898 0.78 MAPT (0.57) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL24124186 0.78 MAPT (0.57) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL24124188 0.78 MAPT (0.62) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL25933321 0.78 HDAC1 (0.45) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL25920636 0.76 MAPT (0.60) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL24124184 0.76 HDAC1 (0.47) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL18569123 0.76 MAPT (0.58) MAPTMEN1KMT2AHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed
WO-2021257544-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 MAPT 4492/4885MEN1 2558/4885KMT2A 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback